Condition: Advanced/Metastatic Breast Cancer · HER2-Positive Metastatic Breast Cancer · Sponsor: Sun Yat-sen University
Efficacy and Safety of Dalpiciclib Combined with Anti-HER2 Targeted Therapy and Endocrine Therapy as First-line Maintenance Treatment for Patients with Recurrent or Metastatic Hormone-Receptor-Positive, HER2-positive Breast Cancer.
This description comes directly from the study's public registry record.
Chen Doctor Chen, PhD / Doctorate · 02087341812 · chenmt@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Sun yat-Sen University Cancer Center, Guangzhou, Yuexiu District | Guangdong, GUANGZHOU, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07610720